New Report Published: Intravenous (IV) Ibuprofen Market Value to Show $14.2 Million by 2022

"Adults end user segment accounted for major share in 2015, and is projected to maintain this trend throughout the forecast period. This is because the IV Ibuprofen was not prescribed for pediatrics until 2014. Pediatrics is projected to be the fastest growing end user segment, owing to the growing need for rapid pain and fever management in children (to avoid damage caused by inflammation and high body temperature) and increasing awareness about the use of IV Ibuprofen in children."

Intravenous (IV) Ibuprofen Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $14.2 million by 2022, registering a CAGR of 20.0% during the period 2016-2022. The pain indication segment accounted for over three-fourths share in 2015 and is expected to maintain its dominance throughout the forecast period.

Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-sample/1387?utm_source=OPR

The major factors that boost the market growth include, increase in adoption of an intravenous mode of drug delivery for acute pain management due to faster onset of action as compared to the other routes (oral and transdermal mode of administration) and targeted drug delivery property. The market growth is further augmented as IV ibuprofen improves pain management with less dependence on opioid analgesic medication, which may lead to several health complications such as sedation, dizziness, and others. Caldolor (Cumberland Pharmaceuticals) is the only injectable ibuprofen drug available in the market; hence, it has huge demand with minimal competition. However, numerous factors are likely to restrain the market growth such as lengthy approval process and limited geographic (country specific) approvals.

Key Findings of IV Ibuprofen Market:

• Fever is projected to be the fastest growing indication segment.
• Australia IV Ibuprofen market is expected to grow at the fastest CAGR of 14.7% from 2015 to 2020.
• In 2015, the U.S. and Canada collectively accounted for more than three-fourths of the global IV Ibuprofen market.

The U.S. is anticipated to remain the highest revenue-generating region during the forecast period, owing to the widespread adoption of IV Ibuprofen for treating pain and fever. However, Australia is expected to grow rapidly during the forecast period, owing to recent entry of IV Ibuprofen in this market, increasing awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards intravenous mode of drug delivery.

Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/1387?utm_source=OPR

The IV Ibuprofen market is dominated by Cumberland Pharmaceuticals and is actively engaged in research for the development of novel IV Ibuprofen products. The key ibuprofen companies profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc. (Acquired by Teligent, Inc.), CSL Limited, Sandor Medicaids Pvt. Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., and Laboratorios Valmorca, C.A.

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.